American Century Companies Inc. Sells 65,409 Shares of aTyr Pharma, Inc. $ATYR

American Century Companies Inc. cut its position in shares of aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) by 74.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,703 shares of the company's stock after selling 65,409 shares during the quarter. American Century Companies Inc.'s holdings in aTyr Pharma were worth $69,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Group One Trading LLC purchased a new stake in aTyr Pharma during the fourth quarter valued at about $26,000. XTX Topco Ltd lifted its stake in aTyr Pharma by 74.9% during the first quarter. XTX Topco Ltd now owns 19,556 shares of the company's stock valued at $59,000 after buying an additional 8,374 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in aTyr Pharma during the fourth quarter valued at about $39,000. Two Sigma Advisers LP purchased a new stake in aTyr Pharma during the fourth quarter valued at about $44,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in aTyr Pharma during the first quarter valued at about $38,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ATYR has been the subject of a number of analyst reports. Jefferies Financial Group upped their price objective on shares of aTyr Pharma from $9.00 to $17.00 and gave the company a "buy" rating in a research note on Friday, August 22nd. Wall Street Zen lowered shares of aTyr Pharma from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Wells Fargo & Company increased their price target on shares of aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, June 20th. Finally, HC Wainwright reiterated a "buy" rating and issued a $35.00 target price on shares of aTyr Pharma in a research report on Wednesday, June 4th. One investment analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company's stock. According to MarketBeat, aTyr Pharma has an average rating of "Buy" and an average price target of $23.25.

aTyr Pharma Stock Down 1.3%

ATYR stock traded down $0.07 during midday trading on Wednesday, reaching $5.24. The company had a trading volume of 4,037,304 shares, compared to its average volume of 2,619,172. aTyr Pharma, Inc. has a 1 year low of $1.67 and a 1 year high of $7.29. The company has a current ratio of 5.63, a quick ratio of 5.63 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $513.45 million, a P/E ratio of -6.55 and a beta of 1.01. The company has a 50 day moving average of $5.35 and a two-hundred day moving average of $4.35.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04). On average, equities research analysts expect that aTyr Pharma, Inc. will post -0.91 earnings per share for the current fiscal year.

aTyr Pharma Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.